SCHEMBL3017484

SCHEMBL3017484

COc1ccc(OC)c(S(=O)(=O)N2CCN(c3nc(-c4cccc(C)c4C)cs3)CC2)c1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.62
MAPT P10636 3/20 0.62
RECQL P46063 2/20 0.62
KMT2A Q03164 4/20 0.54
USP2 O75604 3/20 0.52
HSD17B10 Q99714 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
KDM4E B2RXH2 1/20 0.52
HTT P42858 2/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
REV1 Q9UBZ9 1/20 0.48
MAPK1 P28482 1/20 0.48
POLB P06746 1/20 0.44
HTR6 P50406 1/20 0.44
GAA P10253 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014620 0.93 MAPT (0.52) ALDH1A1MAPTRECQLKMT2AUSP2
SCHEMBL3004687 0.93 ALDH1A1 (0.61) ALDH1A1MAPTRECQLKMT2AUSP2
SCHEMBL3015497 0.90 GAA (0.50) ALDH1A1MAPTRECQLKMT2AUSP2
SCHEMBL15671700 0.90 MAPT (0.50) ALDH1A1MAPTRECQLKMT2AUSP2
SCHEMBL3010691 0.90 ALDH1A1 (0.65) ALDH1A1MAPTRECQLKMT2AUSP2
SCHEMBL3006761 0.89 KMT2A (0.61) ALDH1A1MAPTRECQLKMT2AUSP2
SCHEMBL3022575 0.88 KMT2A (0.58) ALDH1A1MAPTRECQLKMT2AUSP2
SCHEMBL3652353 0.87 MAPT (0.47) ALDH1A1MAPTRECQLKMT2AUSP2
SCHEMBL3010901 0.87 KMT2A (0.57) ALDH1A1MAPTRECQLKMT2AUSP2
SCHEMBL3016127 0.86 MAPK1 (0.56) ALDH1A1MAPTRECQLKMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885MAPT 18/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.